Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to risk of different breast cancer subgroups: a Malmö Diet and Cancer Study

2015 ◽  
Vol 26 (8) ◽  
pp. 1093-1104 ◽  
Author(s):  
Jasmine Brandt ◽  
Signe Borgquist ◽  
Jonas Manjer
2012 ◽  
Vol 131 (9) ◽  
pp. 2126-2133 ◽  
Author(s):  
Ada Tosovic ◽  
Charlotte Becker ◽  
Anne-Greth Bondeson ◽  
Lennart Bondeson ◽  
Ulla-Britt Ericsson ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Olöf Bjarnadottir ◽  
Maria Feldt ◽  
Maria Inasu ◽  
Pär-Ola Bendahl ◽  
Karin Elebro ◽  
...  

AbstractStatins, commonly used to treat hypercholesterolemia, have also been proposed as anti-cancer agents. The identification of a predictive marker is essential. The 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR), which is inhibited by statins, might serve as such a marker. Thorough antibody validation was performed for four different HMGCR antibodies. Tumor expression of HMGCR (#AMAb90619, CL0260, Atlas Antibodies, Stockholm, Sweden) was evaluated in the Malmö Diet and Cancer Study breast cancer cohort. Statin use and cause of death data were retrieved from the Swedish Prescribed Drug Register and Swedish Death Registry, respectively. Breast cancer-specific mortality (BCM) according to statin use and HMGCR expression were analyzed using Cox regression models. Three-hundred-twelve of 910 breast cancer patients were prescribed statins; 74 patients before and 238 after their breast cancer diagnosis. HMGCR expression was assessable for 656 patients; 119 showed negative, 354 weak, and 184 moderate/strong expressions. HMGCR moderate/strong expression was associated with prognostically adverse tumor characteristics as higher histological grade, high Ki67, and ER negativity. HMGCR expression was not associated with BCM. Neither was statin use associated with BCM in our study. Among breast cancer patients on statins, no or weak HMGCR expression predicted favorable clinical outcome. These suggested associations need further testing in larger cohorts.


2017 ◽  
Vol 142 (7) ◽  
pp. 1309-1321 ◽  
Author(s):  
Jasmine Brandt ◽  
Signe Borgquist ◽  
Peter Almgren ◽  
Asta Försti ◽  
Linnea Huss ◽  
...  

2020 ◽  
Vol 61 (10) ◽  
pp. 1326-1334
Author(s):  
Hanna Sartor ◽  
Jasmine Brandt ◽  
Felix Grassmann ◽  
Mikael Eriksson ◽  
Kamila Czene ◽  
...  

Background Genetic factors are important in determining breast density, and heritable factors account for 60% of the variation. Certain single nucleotide polymorphisms (SNPs) are associated with density and risk of breast cancer but the association with prognosis is not clear. Purpose To investigate associations between selected SNPs and breast cancer survival in the Malmö Diet and Cancer Study (MDCS). Material and Methods A total of 724 unrelated women with breast cancer and registered radiological and pathological data were identified in MDCS 1991–2007, with genotyping available for 672 women. Associations among 15 SNPs, density, and breast cancer-specific survival were analyzed using logistic/Cox regression, adjusted for factors affecting density and survival. Variants significantly associated with either density or survival were validated in a large independent breast cancer cohort (LIBRO-1). Results Minor homozygotes of SNPs rs9383589, CCDC170 and rs6557161, ESR1 were associated with high breast density (adjusted odds ratio [AOR] 8.97, 95% confidence interval [CI] 1.35–59.57; AOR 2.08, 95% CI 1.19–3.65, respectively) and poorer breast cancer survival (adjusted hazard ratio [HRadj] 6.46, 95% CI 1.95–21.39; HRadj 2.30, 95% CI 1.33–3.96, respectively) compared to major homozygotes. For SNP rs3757318, ESR1, minor homozygotes (HRadj 7.46, 95% CI 2.28–24.45) were associated with poorer survival. We confirmed that rs6557161, ESR1 was significantly associated with both density and survival in the LIBRO-1 study. Conclusion These findings support a shared genetic basis for density and breast cancer survival. The SNP significantly associated with both density and survival in both cohorts may be of interest in future research investigating polygenic risk scores for breast cancer risk and screening stratification purposes.


The Breast ◽  
2022 ◽  
Author(s):  
Maria Inasu ◽  
Maria Feldt ◽  
Helena Jernström ◽  
Signe Borgquist ◽  
Sixten Harborg

2017 ◽  
Vol 5 (4) ◽  
pp. 692-699 ◽  
Author(s):  
Sachin Dhakal ◽  
◽  
Amar Nagila ◽  
Reetu Koirala ◽  
MahendraPrasad Bhatta ◽  
...  

The Breast ◽  
2015 ◽  
Vol 24 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Hanna Sartor ◽  
Signe Borgquist ◽  
Linda Hartman ◽  
Sophia Zackrisson

Sign in / Sign up

Export Citation Format

Share Document